Division of Cancer Prevention
RFAs and Research Priorities

Barry Kramer, M.D., M.P.H.
Director

Lori Minasian, M.D.
Deputy Director

Division of Cancer Prevention
National Cancer Institute
Realizing Our Research Priorities Using RFAs in a Time of Limited Resources

• Pursue flexibility in opportunities
• Use innovative and efficient approaches to stimulate research
  o Adjust research of core programs
  o Collaborate to build upon common interests
RFA Research Priorities

• Clinical Studies and Large Trials
• Overdiagnosis and Precancerous Lesions
• Partnering on Clinical Studies
Core Programs Using RFAs (FY 2012)

Community Clinical Oncology Program Network
- 3 RFAs ($87 M / U10s)

Early Detection Research Network
- 4 RFAs ($24 M / U01s & U24s)

Alliance of Glycobiologists for Cancer Detection
- 1 RFA ($3.5 M / U01s)

Barrett’s Esophagus Translational Research Network (BETRNet)
- 1 RFA ($2.5 M / U54s)
Community Clinical Oncology Program Network (CCOP)

Funds community physicians’ prevention, control, and treatment clinical trials

- Initiated in 1983
- 3 RFAs:
  - CCOPs (49)
  - Minority-based CCOPs (17)
  - Research Bases (13)
    - Cooperative Groups & Cancer Centers
Early Detection Research Network (EDRN)

Key network for research to identify, test and validate cancer biomarkers for early detection

- Initiated in 2000
- 4 RFAs:
  - Biomarker Developmental Laboratories (20)
  - Clinical Validation Centers (8)
  - Biomarker Reference Laboratories (3)
  - Data Coordinating and Management Center (1)
- Associate Members (130) No RFA Funds
Alliance of Glycobiologists for Cancer Detection (with NIGMS, NHLBI)

Network to study molecular processes by which changes in glycosylation contribute to cancer development

- Initiated in 2007
- 1 RFA for Tumor Glycomics Laboratories (8)
- Other ICs fund additional investigators and laboratories in the Alliance
- Promising glycans can be validated by EDRN
Barrett’s Esophagus Translational Research Network (BETRNet)

Goal is to understand the biology of the preneoplastic lesions and invasive cancer

• Initiated in 2011
• 1 RFA:
  o DCP funds 2 research centers
  o DCB funds 1 research center
    1 coordinating center
Collaborations to Build Upon Common Interests (FY 2012)

Jointly Initiated Projects

• Common Pathogenic Mechanisms of Lung Cancer and COPD (RFA-HL-11-002) with NHLBI ($2.0 M / R01s)
• Biomechanisms of Peripheral Nerve Damage by Anti-Cancer Therapy (PA-12-082 and PA-12-083) with NINDS

Building on Existing Trials for Cancer Endpoints

• Diabetes Prevention Program Outcomes Study NIDDK ($0.7 M / U01s)
• Aspirin in Reducing Events in the Elderly/ ASPREE NIA ($0.9 M / U01)
Upcoming Projects

NCI Community Oncology Research Program (NCORP)
- Two existing programs to be aligned to expand the scope of research to include clinical trials, cancer care delivery, and cancer disparities research
- BSA presentation in June 2013 (tentative)

Improving the Diagnosis of Early Lesions Detected by Cancer Screening (with DCB)
- Characterize cellular and molecular patterns to distinguish indolent vs progressive lesions
- Determine the cellular and molecular phenotypes of early lesion cells and associated microenvironment

NCI Division of Cancer Prevention